Biopolymer-based dermal fillers have gained attention in facial aesthetics due to their biocompatibility, gel-forming properties, and capacity to stimulate tissue regeneration. However, evidence regarding their clinical performance remains scattered and inconsistent. This systematic review evaluates the current scientific literature on the effectiveness and safety of injectable biopolymers used in facial aesthetic procedures. A systematic search was conducted in PubMed, MEDLINE, and Embase databases for studies published between 2016 and 2024. Only human studies in English assessing clinical efficacy, safety, adverse events, and patient satisfaction were included. Of the 280 articles initially identified, 9 met the inclusion criteria. The selected studies showed improvements in facial volume and wrinkle reduction with gel-based biopolymers such as poly-L-lactic acid (PLLA), polycaprolactone (PCL), and polymethylmethacrylate (PMMA). Most studies reported high patient satisfaction and a low incidence of serious adverse effects. However, methodological heterogeneity and limited long-term data reduced the strength of the evidence. While injectable biopolymers appear to be effective and generally safe, current evidence is limited and variable. Further multicenter randomized trials with standardized protocols and longer follow-up periods are needed. Clinicians should apply these materials with caution, ensuring individualized treatment planning and careful risk assessment.
Background: Individuals with Down syndrome exhibit a higher prevalence of periodontal disease, which can lead to implant loss. This study aims to identify genetic markers associated with implant loss in these patients, providing insight into potential predictive and therapeutic approaches. Methods: A systematic analysis was conducted, including both clinical and genetic data from Down syndrome patients with a history of dental implants. Genetic profiling was performed using Transcriptome Analysis Console (TAC version 4.0 Applied BiosystemsTM, Thermo Fisher Scientific, Waltham, MA, USA), focusing on genes previously implicated in periodontal disease and bone metabolism. Statistical analysis identified correlations between genetic variants and implant survival rates. Results: The analysis revealed statistically significant alterations in several genes related to inflammation and bone remodeling. Key findings included alterations in the expression of the genes MMP15, MMP17, S100B, GHR, DNAH6, and ZCCHC14 in patients with implant failure. These genetic markers were strongly correlated with compromised osseointegration and implant loss. These findings underline the role of genetic predisposition in the failure of dental implants among individuals with Down syndrome. Conclusions: Genetic markers, particularly those involved in inflammation and bone metabolism, play a critical role in implant loss among Down syndrome patients with periodontal disease. Recognizing these markers can aid in early diagnosis and personalized treatment strategies, potentially improving implant success rates.